menu
    • menu
    [{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"SLN501","moa":"C3 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Silence Therapeutics \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"SLN501","moa":"C3 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Silence Therapeutics \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"QEL-001","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Quell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"QEL-001","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quell Therapeutics \/ Jeito Capital","highestDevelopmentStatusID":"5","companyTruncated":"Quell Therapeutics \/ Jeito Capital"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"VLP Peanut","moa":"Undisclosed","graph1":"Immunology","graph2":"IND Enabling","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergy Therapeutics \/ AGC Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Allergy Therapeutics \/ AGC Biologics"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BenevolentAI

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed

                            BenevolentAI

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BEN-8744

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BenevolentAI Submits CTA for BEN-8744, an Oral PDE10 Inhibitor, As A First-in-class Treatment For Ulcerative C...

                            Details : BEN-8744 is an orally administered, peripherally restricted small molecule PDE10 inhibitor under development as a first-in-class treatment for ulcerative colitis and with the potential for other indications within inflammatory bowel disease.

                            Product Name : BEN-8744

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 21, 2022

                            Lead Product(s) : BEN-8744

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MiroBio

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed

                            MiroBio

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MB272

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Medicxi

                            Deal Size : $97.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Disea...

                            Details : Funds will primarily be used to advance MiroBio’s two lead antibody candidates into clinical trials and obtain safety and efficacy data in patients with autoimmune diseases. MB272 and MB151 are differentiated, precision-engineered checkpoint receptor a...

                            Product Name : MB272

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            June 29, 2022

                            Lead Product(s) : MB272

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Medicxi

                            Deal Size : $97.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Allergy Therapeutics

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed

                            Allergy Therapeutics

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VLP Peanut

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : AGC Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Allergy Therapeutics Selects AGC Biologics to Manufacture Novel Peanut Allergy Vaccine Candidate

                            Details : Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 31, 2022

                            Lead Product(s) : VLP Peanut

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : AGC Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Silence Therapeutics

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed

                            Silence Therapeutics

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SLN501

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Mallinckrodt Pharmaceuticals

                            Deal Size : $2,024.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501

                            Details : Under the collaboration, Silence is responsible for executing the development program for SLN501 until the end of 1 phase I, after which Mallinckrodt will assume responsibility for clinical development and global commercialization.

                            Product Name : SLN501

                            Product Type : Oligonucleotide

                            Upfront Cash : $20.0 million

                            March 23, 2022

                            Lead Product(s) : SLN501

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Mallinckrodt Pharmaceuticals

                            Deal Size : $2,024.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Quell Therapeutics

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed

                            Quell Therapeutics

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QEL-001

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Jeito Capital

                            Deal Size : $156.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Mo...

                            Details : Proceeds to be used to fund clinical development of QEL-001 in liver transplantation, to accelerate development of its product pipeline across transplantation, neuroinflammatory and autoimmune diseases, and enhance its multi-modular engineered Treg platf...

                            Product Name : QEL-001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 29, 2021

                            Lead Product(s) : QEL-001

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Jeito Capital

                            Deal Size : $156.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Quell Therapeutics

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed

                            Quell Therapeutics

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QEL-001

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Quell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineered Treg Cel...

                            Details : The QEL-001 CAR is specific for HLA-A2, which localizes the activity of the CAR-Tregs to the site of the transplanted organ in HLA-A2 mismatch liver transplant patients (i.e. HLA-A2 negative recipients who received an HLA-A2 positive donor liver).

                            Product Name : QEL-001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            October 27, 2021

                            Lead Product(s) : QEL-001

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Silence Therapeutics

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed

                            Silence Therapeutics

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SLN501

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Mallinckrodt Pharmaceuticals

                            Deal Size : $2,024.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Silence Therapeutics Achieves Another Research Milestone Payment from Mallinckrodt Collaboration for Complemen...

                            Details : The milestone relates to pre-clinical development work on the SLN500 C3 targeting program, highlighting the successful ongoing collaboration between the two companies.

                            Product Name : SLN501

                            Product Type : Oligonucleotide

                            Upfront Cash : $20.0 million

                            April 28, 2021

                            Lead Product(s) : SLN501

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Mallinckrodt Pharmaceuticals

                            Deal Size : $2,024.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth